• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immatics N.V. - Ordinary Shares (NQ:IMTX)

    10.54 +0.29 (+2.78%)
    Streaming Delayed Price Updated: 3:51 PM EDT, Apr 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Immatics N.V. - Ordinary Shares

    < Previous 1 2 Next >
    News headline image
    Immatics Announces Full Year 2025 Financial Results and Business Update
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces $125 Million Underwritten Offering
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Appoints Amie Krause as Chief People Officer
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Appoints Venkat Ramanan as Chief Financial Officer
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Third Quarter 2025 Financial Results and Business Update
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Second Quarter 2025 Financial Results and Business Update
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces First Quarter 2025 Financial Results and Business Update
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Full Year 2024 Financial Results and Business Update
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Pricing of $150 Million Public Offering
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Proposed $150 Million Public Offering
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Second Quarter 2024 Financial Results and Business Update
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Appoints Alise Reicin to Board of Directors
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces First Quarter 2024 Financial Results and Business Update
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Full Year 2023 Financial Results and Corporate Update
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Pricing of $175 Million Public Offering
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Proposed Public Offering
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Announces Third Quarter 2023 Financial Results and Business Update
    From https://immatics.com/
    Via GlobeNewswire
    News headline image
    Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
    From https://immatics.com/
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.